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Background. The pathophysiologic mechanisms that determine the severity of Mediterranean spotted fever
(MSF) and the host-related and microbe-related risk factors for a fatal outcome are incompletely understood.
Methods. This prospective study used univariate and multivariate analyses to determine the risk factors for a fatal
outcome for 140 patients withRickettsia conorii infection admitted to 13 Portuguese hospitals during 1994 –2006 with
documented identification of the rickettsial strain causing their infection.
Results. A total of 71 patients (51%) were infected with the Malish strain of Rickettsia conorii, and 69 (49%) were
infected with the Israeli spotted fever (ISF) strain. Patients were admitted to the intensive care unit (40 [29%]),
hospitalized as routine inpatients (95[67%]), or managed as outpatients (5[4%]). Death occurred in 29 adults (21%).
A fatal outcome was significantly more likely for patients infected with the ISF strain, and alcoholism was a risk factor.
The pathophysiology of a fatal outcome involved significantly greater incidence of petechial rash, gastrointestinal
symptoms, obtundation and/or confusion, dehydration, tachypnea, hepatomegaly, leukocytosis, coagulopathy, azo-
temia, hyperbilirubinemia, and elevated levels of hepatic enzymes and creatine kinase. Some, but not all, of these
findings were observed more often in ISF strain–infected patients.
Conclusions. Although fatalities and similar clinical manifestations occurred among both groups of patients, the
ISF strain was more virulent than the Malish strain. Multivariate analysis revealed that acute renal failure and hyper-
bilirubinemia were most strongly associated with a fatal outcome.
Mediterranean spotted fever (MSF), Israeli spotted fever
(ISF), Indian tick typhus, and Astrakhan spotted fever
are caused by distinct strains of Rickettsia conorii. These
strains exhibit minor antigenic and genotypic differ-
ences and have been hypothesized to cause distinctive
clinical signs, as well as disease of differing severity [1, 2].
In Portugal, MSF is caused by R. conorii Malish and
ISF strains [3]. The incidence of MSF was 8.4 infections
per 10,000 inhabitants during 1989 –2005, a high rate
compared with other countries in the Mediterranean
basin in which MSF is endemic. In the past decade, an
increasing number of cases of the malignant form of
MSF have been described in Portuguese patients [4, 5].
Moreover, based on confirmed diagnoses in the Portu-
guese hospital database (Administração Central do Sis-
tema de Saúde, Portuguese Ministry of Health), the
number of admissions for MSF increased from 176 pa-
tients in 1994 to 446 patients in 2004 [6]. The case fatal-
ity rate during the same period was 3%–7% among hos-
pitalized patients. In 1997, the case fatality rate was very
high in 2 Portuguese hospitals, and in the Beja district,
the rate reached 32% [4].
A study conducted in Beja Hospital by Sousa et al. [4]
from 1994 through 1998 to identify the risk factors as-
sociated with a fatal outcome indicated that delay in an-
tibiotic treatment of rickettsial infection was not the ex-
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planation; instead, the risk of death was related to comorbidities
such as diabetes mellitus. It was suspected that the fatal outcome
might have been related to the ISF strain, which was isolated for
the first time in Portugal in 1997 from patients with fatal infec-
tions [7]. The hypothesis was that the ISF strain might cause
different clinical manifestations than those caused by the Malish
strain, which could lead to a late clinical diagnosis and conse-
quently, to a delay in treatment, thus resulting in a higher num-
ber of severe cases. In 2005, Sousa et al. evaluated the 3 main
signs of infection—fever, rash, eschar—and severity of disease in
patients infected with ISF and Malish strains [3]. They observed
no statistically significant differences in the occurrence of signs,
in particular, the presence or absence of an eschar, in 94 Portu-
guese patients infected with either the Malish or the ISF strains.
In Israel, eschars caused by infection with the ISF strain have
been described in only 4% of cases [8 –10]. Because our previous
studies were not exhaustive, we conducted a larger study to de-
termine the risk factors for death in Portuguese patients who had
a diagnosis of MSF confirmed by identification of the strain
causing the infection.
METHODS
Data Collection and Definitions
Patients were admitted to Portuguese hospitals with a clinical
diagnosis of MSF confirmed by isolation of Rickettsia species
from blood or detection of rickettsial DNA in skin biopsy sample
by polymerase chain reaction (PCR) at the Portuguese National
Institute of Health during 1994 –2006. Additionally, serum sam-
ples were tested for the presence of IgM and IgG antibodies
against R. conorii. Epidemiological, clinical, and laboratory data
were recorded at admission. The onset of symptoms was defined
as the first day on which any of the following symptoms were
observed: fever, chills, rash, headache, or gastrointestinal symp-
toms, such as nausea, vomiting, and/or diarrhea. Alcoholism
was defined as ingestion of 120 g ethanol per day, as well as on the
basis of reports from family members and/or a family physician
about the patient’s habits with respect to alcohol. Respiratory
insufficiency was defined as failure of the exchange of oxygen
and carbon dioxide, pO2 60 mm Hg or pCO2 55 mm Hg.
Congestive heart failure was defined as class III or above on the
New York Heart Association Functional Classification for Con-
gestive Heart Failure. Appropriate antibiotic treatment was de-
fined as therapy that included least 1 antibiotic to whichR. cono-
rii is susceptible. Severity of disease was scored on the basis of
patient admission to the intensive care unit (ICU), Acute Phys-
iology and Chronic Health Evaluation II score (data not shown),
or death.
Laboratory Confirmation of MSF
Isolation of Rickettsia species from blood. A heparinized
blood sample was collected from patients with a presumptive
clinical diagnosis of MSF at hospital admission. Plasma was
tested for rickettsial antibodies by immunofluorescence assay.
Blood culture was performed to isolate Rickettsia, and the strain
causing the infection was identified, as described elsewhere [11].
DNA detection in skin biopsies. At admission, a punch
biopsy was performed to obtain a 5-mm skin sample from the
eschar, if present, or from a rash lesion. Informed consent was
obtained from all subjects, and experiments were performed
with approval of the ethical committees of the hospitals and the
Portuguese National Institute of Health. DNA extraction, PCR,
Table 1. Age and treatment intervals for patients, according to strain of Rickettsia conorii.
Type of infection, variable
Infecting strain
of R. conorii
PMalish ISF
Nonfatal
Age, median, years 63 57 .326
Treatment interval
1st symptom to 1st visit, median, days 4 3 .189
1st visit to appropriate antimicrobial therapy, median, days 0 0 .241
1st symptom to specific therapy, median, days 5 4 .028
Length of stay, median, days 7 6 .081
Fatal
Age, median, years 66 57.5 .114
Treatment interval
1st symptom to 1st visit, median, days 4 3 .618
1st visit to specific therapy, median, days 0 .5 .371
1st symptom to appropriate antimicrobial therapy, median, days 4.5 4 .899
Length of stay, median, days 2 1 .203
NOTE. Bold type indicates significant P values. ISF, Israel spotted fever.
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Table 2. Comparative analysis of epidemiologic, clinical, and laboratory find-
ings for patients infected by Rickettsia conorii, according to infecting strain.
Finding, by type Totala
Patients infected
with each strain
of R. conorii,
no. (%)b
PMalish ISF
Epidemiologic finding
Animal contact 88 44 (94) 36 (88) .465
Tick bite 66 20 (63) 11 (32) .014
Clinical finding
Fever 137 64 (94) 65 (94) .99
Eschar 123 38 (60) 23 (38) .015
Rash
Any 137 65 (96) 63 (91) .463
Maculopapular 120 61 (94) 59 (94) .99
Petechial 8 4 (6) 4 (6) .99
Asthenia 80 39 (95) 35 (90) .426
Headache 77 32 (78) 28 (78) .977
Myalgia 85 38 (84) 34 (85) .943
Arthralgia 69 22 (63) 16 (47) .187
Abdominal pain 70 7 (19) 12 (36) .101
Anorexia 65 27 (73) 19 (68) .653
Nausea 75 14 (35) 22 (63) .016
Vomiting 84 13 (30) 23 (56) .017
Diarrhea 79 11 (28) 17 (44) .135
Prostration 81 27 (64) 26 (67) .822
Obtundation and/or confusion 100 19 (38) 15 (30) .398
Dehydration 72 14 (39) 17 (47) .475
Tachypnea 63 10 (38) 18 (49) .452
Chest pain 53 3 (14) 6 (19) .99
Hepatomegaly 60 9 (29) 9 (31) .866
Splenomegaly 57 2 (7) 3 (11) .660
Comorbidity
Alcoholism 103 9 (18) 9 (17) .892
Tobacco use 87 6 (15) 7 (15) .939
Diabetes 107 5 (10) 4 (7) .737
Cardiac failure 105 8 (16) 6 (11) .443
Respiratory failure 85 2 (5) 4 (9) .677
Chronic renal failure 85 3 (7) 0 .116
Hypertension 89 10 (22) 7 (16) .449
Laboratory findingc
Anemia, hemoglobin level 11 g/dL 118 13 (22) 8 (13) .197
Leukopenia, 4400 leukocytes/L 121 6 (10) 10 (16) .571
Leukocytosis, 11,300 leukocytes/L 121 12 (20) 10 (16) .571
Thrombocytopeniad 122 45 (76) 55 (87) .113
Prothrombin time 13 s 84 19 (48) 24 (55) .544
Partial thromboplastin time 35 s 95 17 (35) 22 (47) .598
Glucose level 110 mg/dL 101 33 (66) 29 (57) .346
Urea leveld 112 29 (56) 32 (53) .796
Creatinine level 1.2 mg/dL 120 36 (60) 32 (53) .461
Sodium level 145 mmol/L 120 30 (52) 26 (42) .283
Potassium level 3.5 mmol/L 116 10 (18) 7 (11) .308
Total bilirubin level 1.2 mg/dL 109 14 (26) 25 (45) .047
Alanine transaminase leveld 120 37 (64) 45 (73) .301
(continued)
and strain characterization were performed, as described else-
where [3].
Serologic analysis. The diagnosis of R. conorii infection was
confirmed when serum samples obtained from patients with
acute infection contained IgM antibodies at a titer of32 and/or
IgG titer of128 or there was a 4-fold increase in titer between
serum samples from patients with acute infection and samples
from convalescent patients [12, 13]. The cutoff for a positive
result for R. conorii infection was established by the Portguese
National Institute of Health on the basis of previous studies in
the Portuguese population and previous studies of Portugal as a
country where MSF is endemic. Serum samples from convales-
cent patients were collected at least 15 days after samples ob-
tained during acute infection.
Statistical analysis. Exploratory data analysis was per-
formed by using tables of frequencies and central tendency and
dispersion measures for continuous variables. Differences were
evaluated by use of Fisher’s exact test or Pearson’s 2 test for
categorical variables and by use of the Mann-Whitney test when
continuous variables did not show a Gaussian distribution. Dif-
ferences were considered to be significant at P  .05. The asso-
ciation between death and each factor was measured by an odds
ratio (OR) obtained with univariate logistic regression models.
The multiple logistic regression model was built by stepwise se-
lection, using the criteria of P  .05 for selection variables and
P  .10 for backward elimination. The goodness-of-fit of the
final model was evaluated by means of Pearson’s 2 test and the
Hosmer-Lemeshow test. Data analysis was performed with Stata
(version 9.0 software; Stata).
RESULTS
From January 1994 through July 2006, a clinical diagnosis of
MSF was confirmed in 140 patients from 13 hospitals. Most of
the patients were from 5 hospitals from southern Portugal: 23
from Hospital Garcia de Orta in Almada, 39 from Centro Hos-
pitalar do Baixo Alentejo in Beja, 32 from Hospital do Espiríto
Santo in Évora, 17 from Hospital Distrital de Faro, and 17 from
Centro Hospital de Setúbal. The remaining 12 patients were
from 8 other hospitals. Most of the cases occurred during sum-
mer; 113 cases (81%) occurred during the period from July to
September.
MSF due to infection with the Malish or ISF strains ofR. cono-
rii was diagnosed in 65 males (46%) and 75 females (54%). The
median age was 60.5 years. Six of the patients were not adults
(i.e.,18 years old): 5 were6 years old, and 1 was 12 years old.
Forty patients (29%) were admitted to an ICU, 95 (67%) were
admitted to a ward, and 5 (4%) were treated as outpatients.
Death due to infection with Malish or ISF strains of R. conorii
occurred in 29 adults (21%; 15 men and 14 women).
MSF was confirmed in 93 patients by isolation of Rickettsia
species from blood and in 47 patients by detection of R. cono-
rii DNA by PCR. Additionally, serologic analysis was per-
formed on 138 serum samples obtained from patients with
acute infection and 53 serum samples obtained from conva-
lescent patients. Of the 138 serum samples from patients with
acute infection, only 4 patients (3%) had a significant level of
IgM and/or IgG antibodies against R. conorii (a titer of 32
and 128, respectively). In these 4 patients, the diagnoses
were further confirmed by detection of rickettsial DNA in
skin biopsy samples by PCR, while culture for Rickettsia was
negative. Forty-six patients were diagnosed by seroconver-
sion observed when serum samples obtained during acute
infection were compared to those obtained during convales-
cence, which is considered as a strong evidence of recent in-
fection. No significant level of IgM or IgG antibodies against
R. conorii was detected in patients with fatal cases of MSF.
Table 2. (Continued)
Finding, by type Totala
Patients infected
with each strain
of R. conorii,
no. (%)b
PMalish ISF
Aspartate transaminase leveld 112 42 (79) 53 (90) .119
-Glutamyl transferase leveld 77 17 (50) 32 (74) .027
Alkaline phosphatase leveld 88 10 (26) 24 (49) .026
Creatine kinase leveld 75 19 (51) 13 (34) .133
C-reactive protein level 0.5 mg/dL 66 34 (97) 31 (100) .343
NOTE. Bold type indicates significant P values. ISF, Israeli spotted fever.
a All patients with available data.
b The percentage is based on the total number of patients infected by each strain.
c Children were excluded from analyses of laboratory data.
d For these laboratory values, the abnormal values observed were considered outside
the normal range limits (either below or above those limits) established by each different
hospital laboratory.
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The patient populations infected with R. conorii ISF or Malish
strains, both those with fatal infections and those with nonfatal
infections, were similar with respect to age, the period of time
between the onset of symptoms and first visit to the physician,
and length of hospitalization (table 1). There was a delay of 1 day
in receipt of treatment for patients with nonfatal Malish strain
infection, compared with patients with nonfatal ISF strain infec-
tion (a median of 5 days vs. a median of 4 days). No significant
difference in the incidence of underlying disease or history of
animal contact was detected between patients infected with the
ISF strain and patients infected with the Malish strain (table 2).
Although there was no difference in the seasonal distribution of
patients infected with either the ISF or Malish strain, a history of
a recognized tick bite was more common in patients infected
with the Malish strain than in those infected with the ISF strain
(20 [63%] vs. 11 [32%]) (table 2).
Comparison of the clinical manifestations of MSF caused by
the Malish strain and that caused by the ISF strain revealed tre-
mendous overlap that would prevent clinical recognition of the
strain involved. Both strains were capable of causing disease that
resulted in each of the signs and symptoms, as well as the path-
ophysiologic conditions that caused abnormal laboratory values
for several markers of organ dysfunction. Moreover, statistical
analysis of the clinical signs, symptoms, and laboratory data at
admission revealed few differences between patients infected
with the Malish strain and those infected with the ISF strain
(table 2). First, an eschar was observed in a significantly higher
percentage of patients infected with the Malish strain (38
[60%]), compared with patients infected with the ISF strain (23
[38%]). However, it should be emphasized that many patients
infected with the Malish strain did not have an eschar (table 2).
The anatomic locations of the eschars were similar for patients
with either Malish or ISF infections. An eschar was often found
in the axilla and/or groin (15 [25%]), legs (15 [25%]), and trunk
(12 [20%]), and only 3 patients infected with R. conorii Malish
strain presented with more than 1 eschar. Second, ISF strain–
infected patients suffered nausea and vomiting more often than
Malish strain–infected patients (table 2), suggesting significant
gastrointestinal involvement in patients with ISF strain infec-
tion. Third, compared with Malish strain–infected patients, a
higher percentage of patients with ISF strain infection had sig-
nificantly elevated serum levels of total bilirubin, -glutamyl
transferase, and alkaline phosphatase, among other altered pa-
rameters (table 2), suggesting greater hepatic involvement.
Of the 6 children infected with R. conorii, 4 were infected with
the Malish strain and 2 with the ISF strain (table 3). The most
severely ill child was a 12-year-old infected with Malish strain
who did not receive treatment until the tenth day of illness. He
developed encephalitis and thrombocytopenia and had mark-
edly elevated serum levels of hepatic transaminases.
The most important observation in this study was a statisti-
cally significantly greater severity of disease in patients infected
with R. conorii ISF strain, compared to those infected with the
Malish strain (table 4). The case fatality rate for ISF strain infec-
tion was significantly greater than that for Malish strain infec-
tion (20 [29%] vs. 9 [13%];P  .02), and a greater percentage of
patients with ISF strain infection required admission to the ICU,
compared to those with Malish strain infection (25 [36%] vs. 15
[22%]; P  .061). Analysis of the relationship between comor-
bidities and a fatal MSF outcome demonstrated that alcoholism
was a statistically significant host condition that was a risk factor
for a fatal outcome (table 4).
Analysis of the clinical and laboratory data for fatal and non-
fatal infections provided a picture of the pathophysiology of se-
vere MSF in a large series of patients who had been documented
specifically to have been infected with R. conorii by isolation of
Rickettsia species or by molecular diagnosis and genetic identifi-
cation of the agent, rather than by a diagnosis based on clinical
manifestations or serologic analysis that did not distinguish
among various spotted fever– group rickettsioses. Patients with
fatal cases of etiologically documented R. conorii infection were
more likely to have severe involvement of multiple organ sys-
tems as indicated by significantly greater occurrence of petechial
rash, nausea, vomiting, diarrhea, prostration, obtundation
and/or confusion, dehydration, tachypnea, and hepatomegaly
(table 4) Also, patients with fatal infection were more likely to
have leukocytosis (11,300 cells/L), prolonged partial throm-
boplastin time, and elevated serum concentrations of urea, cre-
atinine, bilirubin, alanine transaminase, -glutamyl transferase,
alkaline phosphatase, and creatine kinase (table 4) at the time of
admission. Of the patients with fatal cases, 5 did not have rash or
eschar at the time of admission. Fever and rash were present
significantly more often among patients with nonfatal cases,
compared with those who had fatal cases. Multivariate analysis
identified 3 variables as independent predictors associated with
fatal outcome: hyperbilirubinemia (OR, 25.99 [95% confidence
interval {CI}, 5.90 –137.93]; P  .001), acute renal failure (OR,
18.10 [95% CI, 1.89 – 173.35]; P  .012), and absence of rash
(OR, 0.03 [95% CI, 0.00 – 1.22]; P  .064). The results of the
goodness-of-fit test (Hosmer-Lemeshow) showed that the
model behaved with good fitness (P  .125)
Data on antimicrobial therapy were available for 129 adult
patients (64 infected with the Malish strain and 65 infected with
the ISF strain). Doxycycline was the drug most often used to
treat patients with MSF; it was administered to 57 patients (89%)
infected with the Malish strain and to 46 (71%) infected with the
ISF strain. Doxycycline was used in combination with a fluoro-
quinolone for 2 patients (3%) infected with the Malish strain
and for 7 patients (11%) infected with the ISF strain. Six patients
(9%) infected with the ISF strain received therapy with a fluoro-
quinolone alone. Of 64 patients infected with the Malish strain, 2
(3%) received no treatment, 2 (3%) were treated with a-lactam
drug, and 1 (2%) was treated with rifampin. Of 65 patients in-
fected with the ISF strain, 5 (8%) patients received no treatment
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and 1 (2%) was treated with a -lactam drug. No statistically
significant differences were found between the groups of pa-
tients with respect to therapeutic regimens (P  .472). Among
the 7 patients who did not receive treatment, 2 survived and 5
died.
Of the 6 child patients, 3 received treatment with a macrolide
(azithromycin), 1 received chloramphenicol, and 1 received
doxycycline. The 6-month-old child recovered without specific
treatment. No fatal cases occurred in children (table 3).
DISCUSSION
To our knowledge, this study represents the largest case series of
patients with a confirmed diagnosis of MSF based on documen-
tation of R. conorii infection and the largest series that includes
identification of the strain, rather than only clinical diagnosis or
non–species specific serologic diagnosis. Owing to the presence
of shared protein and lipopolysaccharide antigens among spot-
ted fever– group rickettsiae, it is extremely difficult to distin-
guish between infections due to closely related rickettsiae by se-
rologic or immunohistochemical methods [14, 15]. In the
Mediterranean basin, patients with similar clinical manifesta-
tions have been documented (by isolation of Rickettsia species)
to be infected with R. sibirica mongolotimonae strain, R. akari,
and R. massiliae, all of which would have produced antibodies
that were cross-reactive with R. conorii [11, 16, 17]. Isolation
and/or PCR detection followed by genetic characterization can
determine the genotype of the organism to the level of genus,
species, and strain. Previous studies by Sousa et al. (Portugal)
and Giammanco et al. (Italy) compared some of the clinical
manifestations of MSF caused by ISF and Malish strains [3, 18].
Table 3. Clinical and laboratory data for 6 children with Mediterranean spotted fever.
Variable
Patient number
1 2 3 4 5 6
Infecting strain ISF ISF Malish Malish Malish Malish
Age 4 years 6 years 1 years 5 months 6 months 12 years
Treatment interval
1st symptoms to
specific therapy,
days 2 4 4 NA NA 10
Admission to
discharge, days 0 9 9 9 0 11
Clinical sign or
symptom
Fever Yes Yes Yes Yes Yes Yes
Eschar No No No No No Yes
Rash Maculopapular Petechial Maculopapular Maculopapular Maculopapular Maculopapular
Headache . . . . . . . . . . . . . . . Yes
Myalgia . . . . . . . . . . . . Yes Yes
Gastrointestinal signs Vomiting . . . . . . . . . Vomiting . . .
Hepatomegaly . . . . . . . . . . . . . . . . . .
Splenomegaly Yes . . . . . . . . . . . . . . .
Complications . . . . . . . . . . . . . . . Encephalitis
Antimicrobial drugs
received Azithromycin Doxycycline Azithromycin Chloramphenicol None Azithromycin
Laboratory data
Leukocyte count,
cells/L 8920 2260 9930 17,800 . . . 13,870
Platelet count,
platelets/ L 177,000 106,000 137,000 177,000 . . . 88,000
Urea level, mg/dL 21 15 27 . . . . . . . . .
Creatinine level, mg/
dL 0.4 0.5 0.3 0.6 . . . . . .
Alanine transaminase
level, U/L 56 246 347 . . . . . . 826
Aspartate
transaminase level,
U/L 58 285 365 . . . . . . 1117
NOTE. ISF, Israeli spotted fever.
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Table 4. Univariate analysis of epidemiologic, clinical, and laboratory findings in patients with fatal and nonfatal Mediterranean
spotted fever.
Finding, by type Totala
Type of infection, no. (%) of patients
OR adjusted by strain (95% CI) PNonfatal Fatal
Epidemiologic finding
Rickettsial strain
Malish 71 62 (87) 9 (13) 1 . . .
ISF 69 49 (71) 20 (29) 2.81 (1.18–6.72) .020
Animal contactb 88 69 (90) 11 (100) NA NA
Tick bite 66 27 (50) 4 (33) 0.68 (0.17–2.72) .587
Clinical finding
Fever 137 106 (97) 23 (82) 0.11 (0.23–0.54) .006
Eschar 123 53 (52) 8 (36) 0.59 (0.22–1.56) .589
Rash
Any 137 105 (97) 23 (79) 0.12 (0.03–0.52) .005
Maculopapular 102 (97) 18 (78) 1 . . .
Petechial 3 (3) 5 (22) 10.93 (2.29–53.83) .003
Asthenia 80 59 (94) 15 (88) 0.63 (0.097–4.121) .633
Headache 77 47 (76) 13 (87) 2.34 (0.43–12.73) .326
Myalgia 85 58 (83) 14 (93) 3.08 (0.35–27.19) .311
Arthralgia 69 31 (55) 7 (54) 1.19 (0.33–4.23) .792
Abdominal pain 70 11 (29) 8 (57) 4.56 (1.23–16.85) .023
Anorexia 65 37 (66) 9 (82) 2.58 (0.46–14.50) .282
Nausea 75 25 (40) 11 (92) 12.5 (1.48–106.94) .021
Vomiting 84 22 (33) 14 (82) 7.5 (1.88–30.12) .004
Diarrhea 79 16 (26) 12 (71) 6.38 (1.81–22.42) .004
Prostration 81 36 (58) 17 (89) 6.73 (1.37–33.03) .019
Obtundation 100 22 (27) 12 (67) 9.26 (2.61–32.91) .001
Dehydration 72 18 (33) 13 (76) 7.55 (1.95–29.29) .003
Tachypnea 63 11 (25) 17 (89) 29.17 (5.35–158.97) <.001
Chest pain 53 6 (15) 3 (25) 1.79 (0.35–9.18) .486
Hepatomegaly 60 12 (24) 6 (67) 7.37 (1.46–37.04) .015
Splenomegaly 57 4 (8) 1 (17) 2.00 (0.17–23.77) .584
Comorbidity
Alcoholism 103 11 (13) 7 (47) 6.994 (1.99–24.64) .002
Tobacco use 87 10 (14) 3 (18) 1.286 (0.30–5.54) .735
Diabetes 107 8 (9) 1 (6) 0.745 (0.08–6.65) .793
Cardiac failure 105 11 (13) 3 (18) 1.773 (0.41–7.60) .440
Respiratory failure 85 5 (7) 1 (6) 0.705 (0.07–6.79) .763
Chronic renal failure 85 3 (4) 0 . . . . . .
Hypertension 89 13 (18) 4 (25) 1.839 (0.48–7.07) .375
Laboratory findingc
Anemia, hemoglobin level 11 g/dL 118 18 (20) 3 (11) 0.59 (0.15–2.20) .424
Leukopenia, 4400 cells/L 121 13 (14) 3 (12) 1.30 (0.31–5.59) .716
Leukocytosis, 11,300 cells/L 121 10 (11) 12 (46) 11.13 (3.37–36.80) <.001
Thrombocytopenia d 122 73 (78) 27 (96) 6.8 (0.86–53.78) .069
Prothrombin time 13 s 84 34 (50) 9 (60) 2.14 (0.59–7.74) .246
Partial thromboplastin time 35 s 95 22 (29) 17 (85) 36.78 (4.53–298.44) .001
Glucose level 110 mg/dL 101 52 (68) 10 (42) 0.36 (0.14–0.95) .038
Urea leveld 112 36 (42) 25 (93) 21.02 (4.50–98.42) <.001
Creatinine level, 1.2 mg/dL 120 42 (46) 26 (93) 20.81 (4.44–97.46) <.001
Sodium 145 mmol/L 120 48 (52) 8 (29) 0.39 (0.15–0.99) .047
Potassium 3.5 mmol/L 116 15 (16) 2 (8) 0.49 (0.10–2.36) .375
Total bilirubin level, 1.2 mg/dL 109 16 (19) 23 (92) 45.53 (9.62–215.0) <.001
(continued)
This is the first exhaustive study reporting the differences be-
tween patients infected withR. conoriiMalish strain and patients
infected with the ISF strain, as well as the microbe-related and
host-related risk factors and the clinical manifestations associ-
ated with a fatal outcome. In general, patients infected with the
ISF strain and patients infected with the Malish strain did not
show many differences in epidemiological, clinical, or labora-
tory data. The most important findings documented here are
that the ISF strain is more virulent than the Malish strain in the
population investigated and alcoholism is a risk factor for fatal
outcome in MSF. The microbial pathogenic mechanism by
which the ISF strain causes more severe illness remains to be
determined. With regard to host-related risk factors, previous
studies have described alcoholic patients who developed severe
MSF. However, the present study is the first statistical analysis
involving a representative sample that documents alcoholism as
a risk factor for severity of disease [19].
Our data suggest that gastrointestinal symptoms such as nau-
sea, vomiting, and diarrhea (table 4) are prominent manifesta-
tions in patients with fatal MSF. However, these symptoms
might have been related to central nervous system involvement
if intracranial pressure was increased. (i.e., among the patients
with fatal cases, there were many patients with obtundation
and/or confusion [12 {67%}]; rickettsial infection in severe or
fatal cases may result in cerebral edema and increased intracra-
nial pressure, which are features of rickettsial encephalitis, and
nausea and vomiting could be gastrointestinal symptoms that
reflect central nervous system involvement). Thus, the exact
mechanism that accounts for the presence of marked gastroin-
testinal symptoms in patients with fatal cases is not yet clear.
Furthermore, there were significantly greater gastrointestinal
manifestations, such as nausea and vomiting, in patients with
ISF strain infection. It is possible that infection with the virulent
ISF strain causes inflammation of abdominal organs secondary
to rickettsial growth in blood vessels in these tissues or systemic
or local production of high levels of proinflammatory cytokines
and chemokines. This conclusion is consistent with our previous
study showing that patients with severe MSF had very high der-
mal levels of proinflammatory tumor necrosis factor–	, en-
zymes that mediate intracellular bacterial elimination as well as
tissue injury (i.e., inducible nitric oxide synthase and indoleam-
ine dioxygenase), and RANTES, a chemokine that stimulates the
migration and accumulation of T cells at the site of infection
[20].
Multiple logistic regression analysis revealed an independent
significant association between the presence of hyperbiliru-
binemia and fatal outcome in a greater percentage of patients
with ISF strain infection, compared to patients with Malish
strain infection. Whether hyperbilirubinemia is related to cho-
lestasis, hemolysis, or other mechanisms remains to be deter-
mined. Nevertheless, it is clearly evident that hepatic involve-
ment marked by hepatomegaly and elevated serum levels of
alanine transaminase, alkaline phosphatase, and -glutamyl
transferase is strongly associated with a fatal outcome. Histolog-
ical studies have shown that the hepatic pathology in patients
with MSF, namely focal necrosis and mononuclear lobular and
portal triad inflammation, is not associated with fatal disease
[21]. The lack of correlation between pathology and fatal disease
in combination with the strong association between fatal disease
and abnormal values for several laboratory markers of organ
dysfunction confirm the clinical diagnosis of multiple organ sys-
tem involvement as an important factor in fatal rickettsial dis-
eases. Indeed, there was significant evidence of greater injury in
numerous organ systems for patients with fatal cases, compared
with those with nonfatal cases, including injury to vascular en-
dothelium in the brain (obtundation and/or confusion), lungs
(tachypnea), the coagulation system (prolonged partial throm-
boplastin time), and skin (petechial rash). Systemic hypotension
with decreased renal perfusion and glomerular filtration rate are
also most likely the pathophysiologic mechanism behind the
greater incidence of acute renal failure in patients with fatal in-
fections [22].
This study reveals a lower incidence of eschars in patients with
MSF due to the ISF strain, compared with patients infected with
Table 4. (Continued)
Finding, by type Totala
Type of infection, no. (%) of patients
OR adjusted by strain (95% CI) PNonfatal Fatal
Aspartate transaminase leveld 112 70 (81) 25 (96) 4.73 (0.59–38.67) .147
-Glutamyl transferase leveld 77 34 (56) 15 (94) 9.58 (1.16–78.92) .036
Alkaline phosphatase leveld 88 19 (27) 15 (88) 17.52 (3.59–85.44) <.001
Creatine kinase leveld 75 20 (35) 12 (67) 5.06 (1.50–17.09) .009
C-reactive protein level, 0.5 mg/dLb 66 52 (98) 13 (100) . . . . . .
NOTE. Bold type indicates statistically significant P values. CI, confidence interval; ISF, Israeli spotted fever; OR, odds ratio; NA, not available.
a Total patients with available data.
b OR, CI, and P value could not be calculated because there were no fatal cases with normal values.
c Children were excluded from analyses of laboratory data.
d For these laboratory values, the abnormal values observed were considered outside the normal range limits (either below or above those limits)
established by each different hospital laboratory.
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the Malish strain. The significant difference in eschar formation
between MSF due to the ISF strain and that due to the Malish
strain was not detected in our previous study, which we attribute
to the nonrepresentative number of patients involved in our pre-
vious analysis. Consistent with this conclusion is the finding that
many patients infected with the Malish strain in this study also
did not have an eschar, as described previously. Furthermore,
the current study includes a larger number of patients with fatal
infection who were infected with either the Malish or the ISF
strain, and some of them did not have eschars. Similarly, the case
fatality rate for ISF strain infection in this study was significantly
greater than that for Malish strain infection (29% vs. 13%;
P  .02), and a greater percentage of ISF strain–infected pa-
tients required admission to the ICU, compared with Malish
strain–infected patients (36% vs. 22%; P  .061). It is not yet
clear whether the lower incidence of eschar in patients with fatal
ISF strain infection is a prognostic factor that indicates an inef-
fective or detrimental host immune response against Rickettsia
or a confounding factor that causes delayed diagnosis of these
patients and thus disease progression. We favor the first possi-
bility because our data show that the ISF strain–infected patients
received antirickettsial treatment earlier in the course of disease
than the Malish strain–infected patients.
The substantial case fatality rate for MSF in Portugal differs
remarkably from that reported in some other regions of the
Mediterranean area, and there are notable differences between
Portugal’s rate and the rates of countries that are near Portugal,
such as France and Spain. The possibility that some Rickettsia
strains are more virulent than others is a reasonable hypothesis
to examine in such areas. It is conceivable that another, less vir-
ulent human pathogen, such as R. massiliae or R. monacensis,
might be the etiologic agent of spotted fever rickettsiosis in some
geographic locations, such as in the northeast of Spain [23, 24].
The reason for the more frequent occurrence of a history of
tick bite in patients infected with the Malish strain is not evident.
Although different vector species or tick stages could be hypoth-
esized to have transmitted the infection without detection, most
of the cases occurred in similar months for both strains, and
Rhipicephalus sanguineus is the only recognized tick host of R.
conorii in Portugal [25].
The lower incidence of rash and eschar as well as Rickettsia-
specific IgM or IgG antibodies in patients with fatal cases em-
phasizes the need to consider the diagnosis of MSF for patients
with unexplained febrile illness, even in the absence of these
signs and serological markers, in regions where MSF is endemic.
This study reveals that diagnosis by PCR amplification of rick-
ettsial DNA from skin biopsy samples is a useful method for
establishing the etiologic agent. PCR was the only method by
which the diagnosis was established in 47 patients. Additionally,
8 patients were diagnosed by both PCR and blood culture. Of
109 skin biopsy samples examined by PCR in this study, 55
(50%) samples were positive and 54 (50%) were negative for
rickettsial DNA. Among the patients with skin biopsy samples
that were PCR-negative for rickettsial DNA, 22 patients had
rickettsial infection confirmed by serologic analysis.
Further analysis of the genotype of the Rickettsia allows iden-
tification of the agent to the strain level with the potential for
investigation of differences in specific hypothetical virulence
factors including adhesins (outer membrane proteins A and B)
[26 –28], actin mobility (RickA) [29], and membranolytic en-
zymes (phospholipase D and hemolysins A and C) [30 –32]. Ad-
vances in diagnosis and knowledge of the pathogenic mecha-
nisms of rickettsioses require further attention.
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